"Biotechs Pouring Funds into Drug Development, Left Behind?" Concerns Over a 'Premium League' Favoring Only Aesthetic Medicine [KOSDAQ Promotion and Relegation Paradox] ①
The Downside of Relying Solely on Performance Indicators Could Deepen
Aesthetics and Medical Firms as 'Beneficiaries' vs. Biotechs in the 'Second Division'
Potential for Polarization as Passive Funds Flow to Top Groups
① Concerns Over a 'Premium League' Benefiting Only the Aesthetic Medicine Sector
② Technology Transfer Performance as a Standard? ...May Encourage Premature Technology Outflow
③ How Promotion and Relegation Could Actually Revitalize Companies
#A biotech firm preparing for an initial listing recently faced an unexpected question at an investment presentation: "If the company segments, won't it be assigned to the Standard tier?" Even though concrete inclusion standards have yet to be finalized, the market was already assuming the company would end up in the "second division." As the company anticipated receiving unfavorable assessments throughout the IPO process—including demand forecasts, public offering price evaluations, and institutional investor participation—internal and external voices began to suggest reconsidering the timing of the IPO itself. This shows that market perceptions, even ahead of system implementation, are already beginning to determine company futures.
There is growing concern among biotech companies that the promotion and relegation system could actually exacerbate market isolation. If quantitative financial performance becomes the main criterion for inclusion, new drug development companies—required to invest large sums into R&D without current sales—will find themselves fundamentally barred from entering the higher segments.
According to the financial investment industry on July 27, the system under consideration by the Korea Exchange would divide KOSDAQ-listed companies into three segments: "KOSDAQ Select" (tentative name), "Standard," and "Watch List." Around 70 companies with both growth potential and financial soundness would be specially selected for the Select segment, with periodic reviews and replacements of the listed firms. The detailed standards will enter discussion from this month's public hearing and are scheduled to be finalized by the end of September.
For companies included in KOSDAQ Select, favorable conditions for capital inflow are anticipated. The Korea Exchange plans to develop a new index focusing on the top-tier companies, introduce related exchange-traded funds (ETFs) to attract passive inflows, and encourage increased investment from pension funds.
The issue is that such standards may lead to unexpected results, depending on the sector—in particular, for the biotech industry. Many in the market expect strong candidates for inclusion to be medical device companies with steady sales and profits, especially those in the aesthetic medicine sector. For example, leaders in the aesthetic medicine field like Hugel, Classys, and PharmaResearch have continued robust performance growth, with market capitalizations typically around 3 trillion won, placing them among the top 30 KOSDAQ companies. Given their solid financial soundness, cash flow, and relatively straightforward ownership structures, these companies are considered among the best candidates under the finance-centric criteria.
An executive at an aesthetic medicine company stated, "Although it may be premature to make assumptions since detailed guidelines have not yet been determined, entry into the top league would enhance both government confidence and public recognition. This, in turn, could attract inflows from institutions and passive funds, improving supply and demand. Not only could this trigger a re-evaluation of corporate value, but it would also serve as a positive momentum for raising global brand recognition."
Conversely, for new drug development biotechs, the same standards could have the opposite effect. Experts note that even the most technologically advanced companies could fail to qualify if they cannot also demonstrate sales stability—a situation where single performance metrics produce disqualification. An executive at a biotech company commented, "There are plenty of KOSDAQ companies with relatively modest earnings but market capitalizations in the trillions of won. The so-called KOSDAQ discount does not apply equally to the entire market; if both market capitalization and sales stability are made prerequisites, even high-potential blue-chip firms may be held back by the sales requirement, resulting in the undervaluation of their future prospects."
The gap between the upper and standard segments is expected to widen over time. While companies joining the higher segment would benefit from passive capital inflows through index and ETF development—and attract increased attention from pension funds and other long-term capital—companies relegated to the standard segment may experience declining trading volumes and liquidity, and may repeatedly be excluded from funds composed based on premium stock criteria.
Another biotech industry representative said, "Whether a new drug company directly leads clinical trials or serves as a platform transferring technology early on, it is inherently difficult in this industry to generate consistent profits. Judged solely by quantitative metrics, most biotechs are bound to be categorized into the lower league—which runs counter to the foundational spirit of KOSDAQ as a market established to recognize companies with growth potential."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Such concerns are also being voiced by the venture capital (VC) sector, which provides early-stage funding. One VC expert noted, "If companies face heightened risk of being relegated post-listing, resulting outflows of institutional capital—such as from pension funds—will inevitably tighten supply and demand. Ultimately, the virtuous cycle of venture capital that powers investment from start-up through IPO exit could be significantly weakened."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.